Sun Pharma Q4 FY25: Strong Growth & Dividends

  Published 10 months ago

Sun Pharmaceutical reported strong Q4 FY25 results with a 15.6% YoY jump in PBT and a 22.4% rise in EBITDA. India formulations grew 13.6%, while US formulations saw a slight decline. A final dividend of Rs 5.50 per share was recommended.

  • PBT up 15.6% YoY to Rs 3,254.35 crore.
  • EBITDA margin at 28.7% with 22.4% growth.
  • Final dividend of Rs 5.50/share proposed.

You might like these

GST Cut Boosts Footwear, Apparel Stocks

Nxtra, AMPIN Expand Green Energy Deal

LTTS, BITS Pilani & CRENS Partner for National Security

SSWL July Turnover Rises, Profit Dips

Vedanta Rises After J.P. Morgan Support

IOB Q1 Profit Doubles, NPA Falls

Indian Shares Rebound on Trade & Rate Cut Hopes

News that matters the most ⚡